The Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration

Trial Profile

The Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions; Expanded access
  • Sponsors ApoPharma
  • Most Recent Events

    • 01 Apr 2016 Status changed from suspended to recruiting, according to ClinicalTrials.gov record.
    • 25 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top